Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06569095

Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry

Sponsor: Peking University People's Hospital

View on ClinicalTrials.gov

Summary

Presently, multiparameter flow cytometry (MFC) and polymerase chain reaction (PCR) have been used for disease load, including measurable residual disease (MRD), monitoring in patients with myelodysplastic syndrome (MDS). MFC is the most commonly method for disease load evaluation. In patients with acute myeloid leukemia, leukemia stem cells (LSCs) determined using MFC for leukemia load and MRD detection is superior to traditional MFC method. In the investigators previous single center study, the investigators demonstrated that detection of disease load, including MRD, by MFC in patients with MDS-EB is superior to predict outcomes after allogeneic stem cell transplantation. Here, the investigators will perform a multi-center, prospective clinical trial to investigate the predictive values of MDS-SC in patients with MDS-EB who received allografting.

Official title: Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry in Patients Receiving Allotransplantation: a Multi-center, Prospective Clinical Study

Key Details

Gender

All

Age Range

15 Years - 70 Years

Study Type

OBSERVATIONAL

Enrollment

163

Start Date

2024-12-09

Completion Date

2027-12-18

Last Updated

2026-02-24

Healthy Volunteers

No

Interventions

OTHER

Detection of MDS-SC using MFC

The aim of this study is to investigate the predictive values of MDS-SC determined by MFC for patients with MDS-EB who underwent allotransplantation.

Locations (4)

Chinese PLA General Hospital

Beijing, China

Peking University People's Hospital

Beijing, China

Wuhan TongJi Hospital

Wuhan, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, China